what is her2 positive breast cancer
HER2-positive breast cancer is a type of breast cancer where the cancer cells have too much of a protein called HER2 on their surface, which makes them grow and divide faster than usual.
What is HER2-positive breast cancer?
HER2 stands for “human epidermal growth factor receptor 2,” a protein that normally helps control cell growth. In about 15–20% of breast cancers, the tumor cells have extra copies of the HER2 gene, leading to excessive HER2 protein, and these cancers are called HER2-positive. Because HER2 acts like a growth accelerator, HER2-positive cancers tend to be more aggressive and can grow and spread faster than HER2‑negative tumors. The important good news is that they often respond very well to modern treatments that specifically target HER2.
How it’s found
Doctors test breast cancer tissue (from a biopsy or surgery) to see whether it is HER2-positive. Common tests include:
- Immunohistochemistry (IHC), which measures how much HER2 protein is on the cell surface.
- In situ hybridization (ISH/FISH), which looks for extra copies of the HER2 gene inside the cells.
All invasive breast cancers are usually tested for HER2 status because it strongly influences treatment choices.
Symptoms and who gets it
HER2-positive breast cancer often causes the same kinds of symptoms as other breast cancers, such as a new lump, breast shape changes, nipple changes, or skin dimpling or redness. Around one in five people with breast cancer will have a HER2-positive tumor. HER2 positivity can occur in both hormone receptor–positive and hormone receptor–negative breast cancers, which also affects the treatment plan.
Is it inherited?
HER2-positive breast cancer usually arises because of changes in the cancer cells themselves, not because of a mutation you are born with. Current evidence shows that HER2 overexpression in the tumor is not considered an inherited (familial) trait in the way BRCA1 or BRCA2 mutations are.
Treatment in today’s world
In 2026, HER2-positive breast cancer is considered highly treatable, especially when found before it has widely spread. Treatment plans are tailored, but often combine:
- Surgery (lumpectomy or mastectomy).
- Radiation therapy, especially after breast-conserving surgery.
- Chemotherapy, often given before or after surgery.
- HER2-targeted therapies, which are the real game-changers.
Common HER2-targeted drugs (names may vary by country and regimen) include monoclonal antibodies and antibody–drug conjugates that “lock on” to HER2 and help destroy cancer cells while sparing more normal tissue. Because these drugs are so effective, HER2 is no longer automatically seen as a marker of poor prognosis when appropriate treatment is available.
Example mini-scenario
Someone is diagnosed with a 2 cm HER2-positive, hormone receptor–positive tumor. Their team might suggest chemotherapy plus a HER2-targeted drug before surgery to shrink the tumor, then surgery, more targeted therapy, and possibly hormone therapy to reduce the risk of the cancer coming back.
Latest news and discussion flavor
Recent years have seen:
- Expansion of HER2‑targeted drugs into earlier-stage disease and metastatic settings, improving survival and quality of life.
- New drugs for “HER2-low” breast cancers, a related but distinct group where HER2 is present at lower levels.
- Growing community and forum discussions where patients share experiences about side effects, fertility, work, and mental health during long courses of targeted therapy.
On patient forums, you will often see people say that a HER2-positive diagnosis sounded frightening at first, but once they learned how many targeted treatments exist now, they felt more hopeful and focused on getting through each phase of treatment.
Quick HTML table for key points
| Aspect | HER2-positive breast cancer |
|---|---|
| What it is | Breast cancer with high levels of HER2 protein or extra HER2 gene copies, driving fast cell growth. | [1][9][3][5]
| How common | About 15–20% of all breast cancers. | [9][7]
| Behavior | Tends to grow and spread faster than HER2-negative cancers but responds well to targeted drugs. | [9][3][5][7]
| Key tests | IHC and ISH/FISH on tumor tissue to determine HER2 status. | [10][7][9]
| Main treatments | Surgery, radiation, chemotherapy, and HER2-targeted therapies; hormone therapy if hormone receptor–positive. | [8][3][5][7][10]
| Outlook today | Often very good when treated appropriately; HER2 is no longer always a bad prognostic marker. | [3][5][7][8]